Drug Profile
Research programme: immune activating antibodies - Antigenics
Alternative Names: Immune activating antibodies research programme - AntigenicsLatest Information Update: 07 Aug 2006
Price :
$50
*
At a glance
- Originator Unknown
- Developer Antigenics
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Viral infections
Most Recent Events
- 07 Aug 2006 No development reported - Preclinical for Autoimmune disorders in USA (unspecified route)
- 07 Aug 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 07 Aug 2006 No development reported - Preclinical for Viral infections in USA (unspecified route)